Radiomics Group, led by Raquel Perez-Lopez, have developed SALSA (System for Automatic Liver tumor Segmentation And detection ...

In early-stage HCC patients (BCLC 0 and A), CP mRNA was elevated in 67.9% of cases, outperforming AFP, which detected only 46 ...

Strategic insight into the Liver Cancer Treatment Market reveals a high-growth opportunity, especially in Asia-Pacific, driven by a rising patient po ...

HistoSonics is shopping for a potential buyer of its approach to destroying liver tumors with focused sound waves, according ...

There is no standard of care for fibrolamellar liver cancer, no targeted therapies. But that may be changing, thanks to ...

The company said that its test could overcome sensitivity issues with ultrasound and serum alpha-fetoprotein assays that are used to monitor at-risk patients.

Liver transplantation is the sole curative option for HCC, but new therapies prompt reconsideration of transplant timing and ...

HistoSonics today announced 12-month follow-up clinical data from its prospective HOPE4LIVER trials evaluating its ...

designed to evaluate the safety and efficacy of histotripsy for the non-invasive destruction of primary (hepatocellular cancer-HCC) and metastatic liver tumors. This press release features multimedia.

LIVER CANCER, the third leading cause of cancer-related deaths globally, is primarily attributed to hepatocellular carcinoma ...

Bayer announced today initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing Glypican-3 ...